Is Vir Biotechnology, Inc. (VIR) a good stock to buy?

Olyth's institutional analysis of VIR reveals an Altman Z-Score of 1.34 and a Piotroski F-Score of 3/9. These metrics, combined with its 5-year revenue trend ($0.07B most recent), help investors decide if VIR fits their risk profile.

What is the current P/E ratio for VIR?

As of the latest trading session, Vir Biotechnology, Inc. (VIR) has a trailing P/E ratio of -3.12.

Who is the CEO of Vir Biotechnology, Inc.?

The current Chief Executive Officer of Vir Biotechnology, Inc. is Marianne De Backer.

What was VIR's revenue for the last 5 years?

According to its latest income statements, Vir Biotechnology, Inc. reported annual revenues of $0.07B (2025), $0.07B (2024), $0.09B (2023), $1.62B (2022), $1.10B (2021) respectively.

Does VIR pay a dividend?

Vir Biotechnology, Inc. does not currently pay a dividend to its shareholders.

How much debt and cash flow does VIR have?

In its latest reporting period, Vir Biotechnology, Inc. generated $-0.40B in Free Cash Flow against a total debt load of $0.19B.

What is the Price-to-Book (P/B) ratio of Vir Biotechnology, Inc.?

The Price-to-Book (P/B) ratio for Vir Biotechnology, Inc. (VIR) is currently 1.79.

What is the Price-to-Sales (P/S) ratio of VIR?

Based on trailing twelve-month data, Vir Biotechnology, Inc. (VIR) trades at a Price-to-Sales (P/S) ratio of 22.91.

What is Vir Biotechnology, Inc.'s Return on Equity (ROE)?

Vir Biotechnology, Inc. (VIR) has a Return on Equity (ROE) of -49.31%, representing its profitability relative to shareholder equity.

VIR

Vir Biotechnology, Inc. · Healthcare

9.83

3.26%(+0.31)

Pre-Market

Last Updated: — ET

52W L: $4.1652W H: $10.94

VIR NEWS

defenseworld.net

1d ago

Backer Marianne De Sells 72,559 Shares of Vir Biotechnology (NASDAQ:VIR) Stock

Vir Biotechnology, Inc. (NASDAQ: VIR - Get Free Report) CEO Backer Marianne De sold 72,559 shares of the firm's stock in a transaction on Monday, April 6th. The stock was sold at an average price of $9.16, for a total value of $664,640.44. Following the completion of the transaction, the chief executive officer owned 948,145 shares

defenseworld.net

Mar 9

Vir Biotechnology, Inc. $VIR Shares Sold by Citigroup Inc.

Citigroup Inc. reduced its position in Vir Biotechnology, Inc. (NASDAQ: VIR) by 22.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 323,525 shares of the company's stock after selling 92,426 shares during the quarter. Citigroup Inc. owned

businesswire.com

Feb 26

Vir Biotechnology to Participate in Upcoming Investor Conferences

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that members of the management team will participate in the following investor conferences during the month of March: TD Cowen 46th Annual Health Care Conference: Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat on Monday, March 2, 2026, at 3:10 p.m. ET/12:10 p.m. PT in Boston, Massachusetts. Leerink Partners Global Healthcare Conference: Marianne De Backer, M.

businesswire.com

Feb 25

Vir Biotechnology Announces Pricing of Public Offering of Common Stock

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 17,647,058 shares of its common stock at a price to the public of $8.50 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be $150 million, bef.

businesswire.com

Feb 24

Vir Biotechnology Announces Proposed Public Offering of Common Stock

SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced that it intends to offer $200,000,000 of shares of its common stock in an underwritten public offering. In addition, Vir Biotechnology intends to grant the underwriters a 30-day option to purchase up to an additional $30,000,000.

seekingalpha.com

Feb 24

Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish

Vir Biotechnology, Inc. surges on positive Phase 1 data for VIR-5500 and a major global partnership with Astellas in prostate cancer. VIR-5500 demonstrated a favorable safety profile and 45% ORR at higher doses, with Astellas providing $335M upfront and up to $1.37B in milestones. Recent licensing deals and a strong cash position ($781.6M) help offset 2025 net loss of $(438M), while pipeline advances target HDV and multiple oncology indications.

Company Profile

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

408

IPO Date

2019-10-11

Beta

1.66

Websitewww.vir.bio↗

Insider Activity

De Backer Marianne

director, officer: President and CEO

SELL

72,559 SH @ $9.16

2026-04-06

SATO VICKI L

director

SELL

22,000 SH @ $9.07

2026-04-01

Sabatini Brent

officer: SVP, Chief Accounting Officer

SELL

7,711 SH @ $9.12

2026-03-23

O'Byrne Jason

officer: EVP & Chief Financial Officer

SELL

2,500 SH @ $0.00

2026-03-20

O'Byrne Jason

officer: EVP & Chief Financial Officer

BUY

2,500 SH @ $0.00

2026-03-20

SATO VICKI L

director

SELL

21,800 SH @ $9.50

2026-03-02

SATO VICKI L

director

SELL

200 SH @ $9.98

2026-03-02

SATO VICKI L

director

BUY

42,377 SH @ $1.49

2026-02-24

De Backer Marianne

director, officer: President and CEO

SELL

72,559 SH @ $9.16

2026-04-06

SATO VICKI L

director

SELL

22,000 SH @ $9.07

2026-04-01

Sabatini Brent

officer: SVP, Chief Accounting Officer

SELL

7,711 SH @ $9.12

2026-03-23

O'Byrne Jason

officer: EVP & Chief Financial Officer

SELL

2,500 SH @ $0.00

2026-03-20

O'Byrne Jason

officer: EVP & Chief Financial Officer

BUY

2,500 SH @ $0.00

2026-03-20

SATO VICKI L

director

SELL

21,800 SH @ $9.50

2026-03-02

SATO VICKI L

director

SELL

200 SH @ $9.98

2026-03-02

SATO VICKI L

director

BUY

42,377 SH @ $1.49

2026-02-24